Allogene CEO Says Safety Board May Keep Alpha 3 Trial Blinded At Mid-2027 Look
A small statistical allowance on the early look tempers hopes of a positive stop, as the CFO retires and enrollment targets end of next year.
Allogene Therapeutics CEO Zachary Roberts said on the company's third-quarter earnings call that the safety board overseeing its pivotal Alpha 3 lymphoma trial may decline to unblind the data at the mid-2027 interim look, cooling hopes of an early positive readout.
A small allowance on the early look
Allogene develops "off-the-shelf" engineered T cell therapies for cancer and autoimmune disease, and has no approved products. Alpha 3 tests its cema-cel therapy in lymphoma patients who still carry traces of disease, known as MRD-positive, before any clinical relapse.
An analyst from UBS asked whether the trial would stop and unblind at the interim look or continue, noting the small amount of statistical allowance, or alpha, spent there. Roberts said a small amount is allocated to the mid-2027 early look at the main goal, event-free survival. The data safety monitoring board, he said, "may, given the small amount of alpha, look at the data and decide" not to unblind and to continue.
"We don't really have a strong opinion about whether that's likely or not," Roberts said. He said the company will follow the board's guidance and put trial integrity first, since premature disclosure of interim data is a risk it takes "very seriously." Executing the trial and fully enrolling it by the end of next year are the company's "number one, two, and three priorities," he said.
Enrollment pace and the early stumble
Roberts said enrollment has improved in recent months, with per-site productivity up and Korea and Australia screening patients since about mid-summer. He said those regions are expected to remain a relative minority of enrollment, so he is not worried about imbalance affecting how the FDA reads the data.
Asked whether pace has met expectations, he said the early going was slow because care is fragmented in the US and MRD-testable patients were hard to find. The company adjusted its timeline early in the study but has not done so again, he said. An earlier interim futility analysis, he said, showed rapid MRD clearance and a favorable early safety profile.
A CFO exits as ALLO-329 data nears
Chief Financial Officer Geoff Parker retires the day after the call. Annie Yoshiyama, senior vice president of finance, will oversee financial operations while the search for a successor continues, Roberts said.
On Monday, November 9, Allogene will present expanded ALLO-329 autoimmune data at the American College of Rheumatology meeting, with three dose levels and three conditioning approaches. At the ASH meeting, it will share a survey of 152 US hematologists and oncologists on barriers to CAR-T adoption.
Roberts said the next Alpha 3 clinical update is planned for mid-2027, with enrollment complete by the end of that year.
Sources
- Allogene Therapeutics: Q3 Earnings Snapshot | wusa9.com — Associated Press
- Allogene Therapeutics Inc (ALLO) (Q3 2026) Earnings Call Highlights: Alpha 3 Momentum Builds as ... — Yahoo Finance
- Allogene Therapeutics Inc (ALLO) Q3 2026 Earnings Report Preview: What To Look For — Yahoo Finance
- Allogene Therapeutics Reports Third Quarter 2026 Financial — globenewswire.com
- Allogene Highlights Clinical Progress and Next-Generation — globenewswire.com